Tags: Drug.
Cediranib (tentative trade name Recentin) also known as AZD2171 is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007 it underwent Phase I clinical trials for the treatment of non-small cell lung cancer kidney cancer and colorectal cancer in adults as well as tumors of the central nervous system in children.
